27.08.2026
China Is Leaving EVs for Biotech: What It Means for Money
Short answer: China is winding down state support for electric vehicles and chips and turning the same industrial machine toward pharmaceuticals — just as patents on many expensive drugs expire and generics become possible. If the playbook that worked for batteries works for medicine, expect much cheaper treatments, pressure on pharmaceutical margins elsewhere, and a new round of supply-chain dependence.
This is a different format: not a deal breakdown, but a conversation I have been having for several days with clients, friends and colleagues in different countries. I read a lot of research from large banks and corporations, and among my clients and friends are pharmaceutical companies and technology manufacturers — from microchips to cancer drugs. What follows is how I read the trend, not a forecast with a guarantee.
How China won batteries, solar and lidar
China already dominates the production of batteries, solar panels, lidar and electric motors. The reason is structure, not cheap labour. Factories rarely build a whole device; each one makes a single component, and they cluster together. On a street that specializes in batteries you will find the entire chain — from processing raw lithium to the packaging — within walking distance.
Building that elsewhere is extremely expensive. A corporation cannot fund it; only a state can, through subsidies and interest-free credit. That is why it is so hard to repeat in Europe. The result: in China you can buy a car whose interior and ride compare with a luxury German sedan for around $35,000–40,000, and component prices have collapsed — lidar units that once cost tens of thousands of dollars now cost a fraction of that.
Why medicine is next
- The patent cliff. Patents on many expensive treatments are expiring, opening the door to generics for serious diseases over the next few years.
- Faster trials. From what I hear from people in the industry, China has sharply shortened the path from development to approval compared with the traditional decade of human trials.
- State money. The same subsidy model that built the battery clusters is being pointed at pharmaceuticals.
I expect the main competition to come from India, and the main customer to remain the United States — unless something else changes.
What it means for money
- For patients and payers: treatments that were unaffordable may become mass-market within five to ten years.
- For pharmaceutical companies elsewhere: pricing pressure on anything that can be made as a generic, and a stronger reason to compete on what cannot.
- For manufacturers and investors: the clustering model is the lesson. Industries that depend on a single concentrated supply base carry a risk that does not show up on the balance sheet until it does.
None of this is a conspiracy theory. It sits on the surface and can be checked. The world has learned to build robots and self-driving cars; within the next decade it may learn to mass-produce treatments for diseases that used to be fatal. How economies and societies adapt to that is the bigger question.
Frequently asked questions
Is China really reducing support for electric vehicles?
Direct purchase subsidies for EVs have been phased out, and policy attention is shifting toward other strategic sectors, including biotechnology and pharmaceuticals.
Why can’t other countries copy China’s industrial clusters?
Because the whole supply chain has to be built at once and financed for years before it pays back. That takes state-level subsidies and credit, which private companies cannot provide.
Who is China’s main competitor in generic drugs?
India, which already supplies a large share of the world’s generics.
This is my view, not investment, legal or tax advice. Check the numbers for your own situation with licensed professionals.
Thinking about how shifts like this affect a company you own or plan to buy? Fill in the questionnaire.